Zeta CEA-P Antibody. Zeta’s polyclonal antibody recognizes CEA-P, a glycosyl phosphatidyl inositol (GPI) cell surface anchored glycoproteins that function as a ligand for various selectins and is used as a tool to assist in the distinction between adenocarcinoma and epithelioid malignant mesotheliomas. The CEA-P antibody can be used to immunophenotype various metastatic adenocarcinomas as a means of identifying their origin within a panel of different markers. CEA-P antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbladder, urachus, salivary gland, ovary, and endocervix. The CEA-P antibody is useful in staining hepatocellular carcinoma in a canalicular pattern.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.